Verismo Therapeutics’ SynKIR-110 receives fast track designation from FDA
SynKIR-110 is an investigational drug to treat mesothelin-expressing mesothelioma, ovarian cancer and cholangiocarcinoma.
Oncology Clinical Trial Trends in the US
Vita Therapeutics raises funds for cell therapies development
Scribe and Sanofi partner to develop cell therapies for cancer
UK NICE grants approval for breast cancer drug combination
Fennec’s hearing loss drug for cancer patients wins breakthrough FDA nod
Abpro and Celltrion partner to develop antibody for cancer
ESMO 2022: data updates push immunotherapy’s scope in cervical cancer
RayzeBio raises $160m to advance cancer radiopharmaceuticals
